Company profile: Artiva Bio
1.1 - Company Overview
Company description
- Provider of allogeneic NK cell therapies and an umbilical cord blood–based manufacturing platform for off-the-shelf use. Products include AlloNK, a non-genetically modified NK therapy enhancing monoclonal antibody or NK engager activity in trials for autoimmune diseases and cancers; AB-201, a clinical-stage HER2-targeted CAR-NK for solid tumors; and AB-205, a preclinical CAR-NK for CD5+ T-cell lymphomas.
Products and services
- Cell Therapy Manufacturing Platform and Infrastructure: Large-scale platform produces allogeneic NK cells from umbilical cord blood, cryopreserves off-the-shelf doses, treating hundreds to thousands of patients from a single donor unit
- AlloNK: Non-genetically modified allogeneic NK cell therapy enhances the activity of monoclonal antibodies or NK cell engagers, with clinical trials in autoimmune diseases and cancers
- AB-201: Cryopreserved, clinical-stage CAR-NK therapy targets HER2-positive solid tumors and is engineered for large scale to support outpatient use
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Artiva Bio
Ikena Oncology
HQ: United States
Website
- Description: Provider of novel biomarker-driven targeted cancer therapies, advancing a pipeline focused on the Hippo and RAS signaling pathways to address cancer growth, spread, and resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ikena Oncology company profile →
Arc Medical
HQ: United Kingdom
Website
- Description: Provider of award-winning, innovative medical products designed to increase Adenoma Detection Rates (ADR) and improve retrieval methods, focusing on enhancing physician experience and patient outcomes with cost effectiveness.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arc Medical company profile →
Progenics Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics for cancer and related conditions, developing PSMA-targeted radioligand therapies (PNT2002, LNTH-1095), diagnostic imaging agents (LNTH-1404), and antibodies (PSMA-TAC), plus a somatostatin receptor-targeted radioligand therapy (PNT2003) for neuroendocrine tumors, alongside pipeline candidates such as PSMA ADC and LNTH-1558 in various clinical and preclinical stages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Progenics Pharmaceuticals company profile →
ArriVent BioPharma
HQ: United States
Website
- Description: Provider of pharmaceutical product development to cure presently untreatable cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArriVent BioPharma company profile →
Janux Therapeutics
HQ: United States
Website
- Description: Provider of immunotherapies that activate T cells in the tumor microenvironment while sparing healthy tissue, including PSMA-TRACTr (JANX007) for metastatic castration-resistant prostate cancer and EGFR-TRACTr (JANX008) in Phase 1 for carcinomas, built on proprietary TRACTr and TRACIr bispecific platforms; partnered with Merck to develop next-generation T cell engager immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Janux Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Artiva Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Artiva Bio
2.2 - Growth funds investing in similar companies to Artiva Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Artiva Bio
4.2 - Public trading comparable groups for Artiva Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →